The University of Chicago Genomics Core Facility (GCF) is committed to providing on-campus biomedical researchers (ranging from experts in the field of genomics to those unfamiliar with whole genome and bioinformatics approaches) with access to state-of-the-art genomics resources (next- Generation Sequencing, DNA microarrays, Sanger Sequencing and non-array based genotyping). The GCF was created in 2006 through the merger of two existing University of Chicago Facilities (the UCCCC-supported DNA Sequencing and Genotyping Facility and the Functional Genomics Facility). The GCF continued to offer access to the main genomics services already provided (Sanger sequencing, DNA microarrays, and array-associated bioinformatics support), while adding next-generation sequencing (NGS) services and NGS-associated bioinformatics support. The merger provided a single on-campus contact point for end-users to fulfill all their genomics needs while operationally eliminating the need for many duplicate pieces of auxiliary equipment (e.g., Nanodrop, Bio-Analyzer), as well as allowing far greater flexibility in managing the human work force as demand for services shift over time. Currently, the GCF is operating as two tightly interactive data generating subunits, "Next-Generation Sequencing and Microarrays" and "DNA Sequencing and Genotyping", housed together in the Knapp Center for Biomedical Discovery (KCBD) since 2009. lllumina and LifeTech NGS services were added in 2010-2011, and an overall GCF Operational Director, was hired in 2011. Also in 2011, the data analysis component ofthe GCF (primarily microarray support) was incorporated into the newly created Bioinformatics Facility at the University of Chicago to avoid duplication of services.

Public Health Relevance

The GCF provides access to state-of-the-art genomics platforms. These resources have become so integral to cutting-edge research in the biological sciences that virtually every investigator will access them on a regular basis making on-campus access to these resources invaluable to both expert and novice genomics investigators.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Chicago
United States
Zip Code
Feng, Christine H; Gerry, Emily; Chmura, Steven J et al. (2015) An image-guided study of setup reproducibility of postmastectomy breast cancer patients treated with inverse-planned intensity modulated radiation therapy. Int J Radiat Oncol Biol Phys 91:58-64
Ming, Mei; Zhao, Baozhong; Shea, Christopher R et al. (2015) Loss of sirtuin 1 (SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous allergen challenge. J Allergy Clin Immunol 135:936-45.e4
Ming, Mei; Zhao, Baozhong; Qiang, Lei et al. (2015) Effect of immunosuppressants tacrolimus and mycophenolate mofetil on the keratinocyte UVB response. Photochem Photobiol 91:242-7
Shah, Palak; He, Yu-Ying (2015) Molecular regulation of UV-induced DNA repair. Photochem Photobiol 91:254-64
Ming, Mei; Han, Weinong; Zhao, Baozhong et al. (2014) SIRT6 promotes COX-2 expression and acts as an oncogene in skin cancer. Cancer Res 74:5925-33
Ramírez, Jacqueline; Kim, Tae Won; Liu, Wanqing et al. (2014) A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469. Pharmacogenet Genomics 24:129-32
Rudra, Sonali; Al-Hallaq, Hania A; Feng, Christine et al. (2014) Effect of RTOG breast/chest wall guidelines on dose-volume histogram parameters. J Appl Clin Med Phys 15:4547
Weng, Liming; Ziliak, Dana; Lacroix, Bonnie et al. (2014) Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One 9:e93420
Stumpf, Melanie; Zhou, Xuyu; Chikuma, Shunsuke et al. (2014) Tyrosine 201 of the cytoplasmic tail of CTLA-4 critically affects T regulatory cell suppressive function. Eur J Immunol 44:1737-46
Geeleher, Paul; Cox, Nancy J; Huang, R Stephanie (2014) Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol 15:R47

Showing the most recent 10 out of 354 publications